Effect of 1 year daily treatment with 400 μg budesonide (Pulmicort® Turbuhaler®) in newly diagnosed asthmatics

European Respiratory Journal

Volumn 10, Issue 10, 1997, Pages 2210-2215

  Osterman, K ^a,e   Carlholm, M ^d   Ekelund, J ^d   Kiviloog, J ^b   Nikander, K ^d   Nilholm, L ^b   Salomonsson, P ^a   Strand, V ^a   Venge, P ^c   Zetterstrom O ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d ASTRAZENECA R AND D   (Sweden)

^e Asthma Allergy Clinic   (Sweden)

Author keywords

Asthma; Bronchial hyperresponsiveness; Budesonide; Eosinophil cationic protein; Peak expiratory flow rate; Turbuhaler

Indexed keywords

BUDESONIDE; TERBUTALINE;

ARTICLE; ASTHMA; BRONCHUS REACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 9844250203     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.97.10102210     Document Type: Article

References (20)

1. Barnes PJ. The changing face of asthma. Q J Med 1987; 63: 359-365.
2. British Thoracic Society/Royal College of Physicians. Guidelines for management of asthma in adults: I. chronic persistent asthma. BMJ 1990; 301: 651-653.
3. Juniper EF, Kline PA, Vanzeileghem M, Hargreave FE. Reduction of budesonide after a year of increased use: a randomized controlled trial to evaluate whether improvements in airway responsiveness and clinical asthma are maintained. J Allergy Clin Immunol 1991; 87: 483-489.
4. Haahtela T, Järvinen M, Kava T, et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 1994; 331: 700-705.
5. 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991; 325: 388-392.
6. Zetterström O, Carlholm M, Ekelund J, Nikander K. Bronchial provocation with histamine in healthy subjects and asthmatics using dosimeter nebulization with controlled tidal breathing. Eur Respir J 1993; 6: Suppl. 17, 598s.
7. Quanjer Ph, ed. Standardized lung function testing. Clin Resp Phys 1983; 19 (Suppl. 5): 45-51.
8. Nieminen MM, Lahdensuo A, Kellomaeki L, Karvonen J, Muittari A. Methacholine bronchial challenge using a dosimeter with controlled tidal breathing. Thorax 1988; 43: 896-900.
9. Peterson CGB, Enander I, Nystrand J, Anderson AS, Nilsson L, Venge P. Radioimmunoassay of human eosinophil cationic protein (ECP) by an improved method: establishment of normal levels in serum and turnover in vivo. Clin Exp Allergy 1991; 21: 561-567.
10. Håkansson L, Westerlund D, Venge P. New method for the measurement of eosinophil migration. J Leukocyte Biol 1987; 42: 689-696.
11. Venge P, Dahl R, Håkansson L, Pettersson C. Generation of heat-labile chemotactic activity in blood after inhalation challenge and its relationship to neutrophil and monocyte/macrophage turnover and activity. Allergy 1982; 37: 55-62.
12. Lorentzon S, Boe J, Eriksson G, Persson G. Use of inhaled corticosteroids in patients with mild asthma. Thorax 1990; 45: 733-735.
13. Vathenen AS, Knox AJ, Wisniewski A, Tattersfield AE. Time course of change in bronchial reactivity with an inhaled corticosteroid in asthma. Am Rev Respir Dis 1991; 143: 1317-1321.
14. Selroos O, Pietinalho A, Löfroos AB, Riska H. The effect of early versus late intervention with inhaled corticosteroids in asthma. Chest 1995; 108: 1228-1234.
15. Woolcock AJ, Jenkins C. Corticosteroids in the modulation of bronchial hyperresponsiveness. Immunol Allergy Clin North Am 1990; 10(3): 543-557.
16. Postma DS, Kerstjens HAM, Koëter GH. Long-term intervention in disease outcome. In: Postma DS, Gerritsen J, eds. Bronchitis V: Proceedings of the Fifth International Symposium on Advances in Understanding of Asthma and COPD. Groningen, The Netherlands, June 9-11, 1993. Van Gorcum, Assen 1994; pp. 253-256.
17. International Consensus Report on Diagnosis and Treatment of Asthma. National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892, Publication No. 92-3091 , March 1992. Eur Respir J 1992; 5: 601-641.
18. Sorva R, Metso T, Björksten F, Juntunen-Backman K, Haahtela T. Sputum ECP is a sensitive asthma marker in children. Allergy Clin Immunol News 1994; 6 (Suppl. 2): 143.
19. Ädelroth E, Rosenhall L, Johansson SA, Linden M, Venge P. Inflammatory cells and eosinophilic activity in asthmatics investigated by bronchoalveolar lavage: the effects of antiasthmatic treatment with budesonide or terbutaline. Am Rev Respir Dis 1990; 142: 91-99.
20. Venge P, Dahl R, Karlström R, Pedersen B, Peterson CG. Eosinophil and neutrophil activity in asthma in a one year double-blind trial with theophylline and two doses of inhaled budesonide. J Allergy Clin Immunol 1992; 89: 190.